- Home
- VYGR
as 12-20-2024 4:00pm EST
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 342.5M | IPO Year: | 2015 |
| Target Price: | $16.44 | AVG Volume (30 days): | 485.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.47 | EPS Growth: | -62.72 |
| 52 Week Low/High: | $5.19 - $11.72 | Next Earning Date: | 11-12-2024 |
| Revenue: | $163,784,000 | Revenue Growth: | 3.40% |
| Revenue Growth (this year): | -63.62% | Revenue Growth (next year): | -22.70% |
Stock Insider Trading Activity of Voyager Therapeutics Inc. (VYGR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Fahey Sandell Jacquelyn | VYGR | Chief Legal Officer | Oct 2 '24 | Sell | $5.82 | 5,999 | $34,914.18 | 86,001 |
Latest Voyager Therapeutics Inc. News
VYGR Breaking Stock News: Dive into VYGR Ticker-Specific Updates for Smart Investing
Zacks
5 days ago
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025
Simply Wall St.
11 days ago
Institutional investors own a significant stake of 48% in Voyager Therapeutics, Inc. (NASDAQ:VYGR)
Zacks
19 days ago
Wall Street Analysts See a 152.53% Upside in Voyager Therapeutics (VYGR): Can the Stock Really Move This High?
TipRanks
22 days ago
Wedbush upgrades Voyager to Outperform on pipeline progress
MT Newswires
23 days ago
Wedbush Upgrades Voyager Therapeutics to Outperform From Neutral, Raises Price Target to $11 From $7
MT Newswires
a month ago
Voyager Therapeutics Selects Development Candidate for Tau Silencing Program in Alzheimer's Disease
GlobeNewswire
a month ago
Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease
Simply Wall St.
a month ago
Declining Stock and Decent Financials: Is The Market Wrong About Voyager Therapeutics, Inc. (NASDAQ:VYGR)?
Compare VYGR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VYGR Voyager Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.